Trials / Completed
CompletedNCT02244762
Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment
Evaluation of the Effect of Renal Impairment on the Pharmacokinetics and Metabolism of Hydrocodone and Its Metabolites Following Administration of Hydrocodone Bitartrate Extended-Release (HC-ER) 20 mg Capsules
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Zogenix, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
Determine the influence of renal impairment on the pharmacokinetics and metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) 20 mg capsules
Detailed description
Pharmacokinetics and relative bioavailability of hydrocodone and its metabolites under fasted conditions
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 20 mg HC-ER | 1-72 hours |
| DRUG | 20 mg HC-ER | 1-72 hours |
| DRUG | 20 mg HC-ER | 1-72 hours |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2011-05-01
- Completion
- 2011-05-01
- First posted
- 2014-09-19
- Last updated
- 2022-11-10
Source: ClinicalTrials.gov record NCT02244762. Inclusion in this directory is not an endorsement.